New Delhi, April 26
India’s drug regulator has granted emergency use authorisation for Biological E’s Covid-19 vaccine Corbevax for those aged five to 12 years and Bharat Biotech’s Covaxin for children in the age group of six to 12 years, official sources said on Tuesday.
The approval by the Drugs Controller General of India (DCGI) comes following recommendations by the Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation(CDSCO).
The SEC had last week reviewed the application of both the companies seeking emergency use authorisation for Corbevax and Covaxin for use in children of five to 12 years and six to 12 years age group, respectively.
Biological E’s Corbevax is being used to inoculate children against Covid-19 in the age group of 12 to 14 years. Covaxin has been granted Emergency Use Listing (EUL) by the DCGI for the age group of 12 to 18 years on December 24, 2021.
India began inoculating children aged 12-14 on March 16.
